Xenolung
End-Stage Lung Disease
PreclinicalResearch & Development
Key Facts
Indication
End-Stage Lung Disease
Phase
Preclinical
Status
Research & Development
Company
About United Therapeutics
Founded on a personal mission to treat pulmonary arterial hypertension, United Therapeutics has grown into a diversified, multi-platform biotech leader with a $26B+ market cap. The company successfully commercializes a portfolio of PAH therapies while aggressively pursuing its 'Mozart' moonshot to create an unlimited supply of transplantable organs. This dual strategy balances near-term financial strength from its rare disease franchise with transformative, long-term value creation in organ manufacturing and regenerative medicine.
View full company profileOther End-Stage Lung Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Inspirex™ Lung | Xylyx Bio | Preclinical |